University of Massachusetts

Medarex Inc.

Centers for Disease Control and Prevention

Acambis Inc.

Oravax-merieux Co.

E. R. Squibb Sons, Inc.

Sanofi Pasteur Biologics, LLC

Oravax, Inc.

William D Thomas, Jr

Gregory Babcock

Donna Ambrosino

Robert Barry Mandell

Thomas P Monath

Teresa J Broering

Hector Javier Hernandez

Israel Lowy

Robert F Graziano

Deborah Molrine

Hui-Fen Zhang

Zhenxi Zhang

Wende Lei

Paul J Giannasca

Susan Sloan

Charles E Rupprecht

Yang Wang

Gopalan Soman

Mark S J Klempner

Naomi K Boatright

Thomas Greenough

John Sullivan

Mohan Somasundaran

Katherine Luzuriaga

Gregory J Babcock

Theresa Broering

Robert Mandell

The invention provides anti-OspA antibodies and methods of using the same.

Anti-OSPA antibodies and methods of use

The invention provides human antibodies against rabies and methods of using the same.

Human antibodies against rabies and uses thereof

The invention provides active and passive immunization methods for preventing and treatinginfection, which involve percutaneous administration oftoxin-neutralizing polyclonal immune globulin,toxoids, or combinations thereof. Also provided by the invention aretoxoids,toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that producetoxin-neutralizing polyclonal immune globulin.

[object Object]

Antibodies that specifically bind to toxins of, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.

Antibodies against clostridium difficile toxins and uses thereof

Isolated human monoclonal antibodies which bind to hepatitis C virus (HCV), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Human antibodies against hepatitis C virus (HCV) and uses thereof

Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.

Codon-optimized nucleic acids, polypeptides, and antibodies are described herein.

SARS nucleic acids, proteins, antibodies, and uses thereof

Active immunization against clostridium difficile disease

The invention provides methods for stabilizing recombinant Helicobacter urease by genetically modifying a urease amino acid. The stabilized urease is prevented from the molecular aggregation or activation (e.g., in vitro activation) characteristic of untreated urease.

Stabilization of helicobacter urease

The invention provides active and passive immunization methods for preventing and treating infection, which involve percutaneous administration of toxin-neutralizing polyclonal immune globulin, toxoids, or combinations thereof. Also provided by the invention are toxoids, toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce toxin-neutralizing polyclonal immune globulin.

Passive immunization against clostridium difficile disease

Growing community of inventors

Somerville, MA, United States of America

William D Thomas, Jr